5 results match your criteria: "and Uganda Virus Research Institute[Affiliation]"
Lancet Infect Dis
March 2018
HIV Department, World Health Organization, Geneva, Switzerland.
Background: Pretreatment drug resistance in people initiating or re-initiating antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and middle-income countries (LMICs). We aimed to assess the scale of this problem and whether it is associated with the intiation or re-initiation of ART in people who have had previous exposure to antiretroviral drugs.
Methods: This study was a systematic review and meta-regression analysis.
J Acquir Immune Defic Syndr
November 2015
*Mbarara University of Science and Technology, Mbarara, Uganda; †University of California, San Francisco, CA; ‡Infectious Diseases Institute, Kampala, Uganda; §Uganda Cancer Institute, Kampala, Uganda; ‖Centers for Disease Control and Prevention, Atlanta, GA; ¶Massachusetts General Hospital, Center for Global Health, Harvard Medical School, Boston, MA; and #Uganda Virus Research Institute, Entebbe, Uganda.
Background: Other than Kaposi sarcoma (KS)-associated herpesvirus and CD4 T-cell lymphopenia, the mechanisms responsible for KS in the context of HIV are poorly understood. One recently explored pathway of HIV pathogenesis involves induction of the enzyme indoleamine 2,3-dioxygenase-1 (IDO), which catabolizes tryptophan into kynurenine and several other immunologically active metabolites that suppress T-cell proliferation. We investigated the role of IDO in the development of KS in HIV disease.
View Article and Find Full Text PDFN Engl J Med
January 2014
University of Zimbabwe, College of Health Sciences, Harare (M.B.-D., K.N., T.M.); the Medical Research Council Clinical Trials Unit at University College London (L.K., M.J.S., D.M.G., A.S.W., A.J.P.) and Centre for Paediatrics, Blizard Institute, Queen Mary, University of London (A.J.P.), London; and the Paediatric Infectious Diseases Clinic of Baylor Uganda, Mulago Hospital (S.B.-K., A.K., P.K.), and Joint Clinical Research Center (R.K., V.M.), Kampala, and the Medical Research Council and Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe (P.N.-N., J.L., P.M.) - all in Uganda.
Background: Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antiretroviral therapy (ART) reduces morbidity in children infected with the human immunodeficiency virus (HIV). We investigated whether children and adolescents receiving long-term ART in sub-Saharan Africa could discontinue co-trimoxazole.
Methods: We conducted a randomized, noninferiority trial of stopping versus continuing daily open-label co-trimoxazole in children and adolescents in Uganda and Zimbabwe.
J Acquir Immune Defic Syndr
June 2006
Centers for Disease Control and Prevention (CDC)-Uganda, Global AIDS Program, National Center for HIV, STD, and TB Prevention, CDC, and Uganda Virus Research Institute, Entebbe, Uganda.
Objective: In Africa, prevention of mother-to-child HIV transmission (PMTCT) programs are hindered by limited uptake by women and their male partners. Routine HIV counseling and testing (HCT) during labor has been proposed as a way to increase PMTCT uptake, but little data exist on the impact of such intervention in a programmatic context in Africa.
Design And Methods: In May 2004, PMTCT services were established in the antenatal clinic (ANC) of a 200-bed hospital in rural Uganda; in December 2004, ANC PMTCT services became opt-out, and routine opt-out intrapartum HCT was established in the maternity ward.
AIDS
July 2005
CDC-Uganda, Global AIDS Program, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention (CDC), and Uganda Virus Research Institute, Entebbe, Uganda.
Background: The effect of cotrimoxazole prophylaxis taken by persons with HIV on community health and antimicrobial resistance is unknown.
Objective: To assess the effect of cotrimoxazole prophylaxis taken by persons with HIV on morbidity, mortality, and antimicrobial resistance of diarrheal pathogens infecting their HIV-negative family members.
Design: Prospective cohort in rural Uganda.